PT1749029E - Moléculas de ligação capazes de neutralizar o vírus da raiva, e suas utilizações - Google Patents

Moléculas de ligação capazes de neutralizar o vírus da raiva, e suas utilizações Download PDF

Info

Publication number
PT1749029E
PT1749029E PT05747901T PT05747901T PT1749029E PT 1749029 E PT1749029 E PT 1749029E PT 05747901 T PT05747901 T PT 05747901T PT 05747901 T PT05747901 T PT 05747901T PT 1749029 E PT1749029 E PT 1749029E
Authority
PT
Portugal
Prior art keywords
binding molecules
rabies virus
molecules capable
neutralizing
virus
Prior art date
Application number
PT05747901T
Other languages
English (en)
Inventor
Alexander Berthold Hendrik Bakker
Willem Egbert Marissen
Robert Arjen Kramer
Cornelis Adriaan De Kruif
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of PT1749029E publication Critical patent/PT1749029E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
PT05747901T 2004-05-27 2005-05-26 Moléculas de ligação capazes de neutralizar o vírus da raiva, e suas utilizações PT1749029E (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US57502304P 2004-05-27 2004-05-27
EP2004050943 2004-05-27
EP2004051661 2004-07-29
EP2004052286 2004-09-23
EP2004052772 2004-11-03
EP2005050310 2005-01-25
EP2005050953 2005-03-03

Publications (1)

Publication Number Publication Date
PT1749029E true PT1749029E (pt) 2011-06-27

Family

ID=34968690

Family Applications (3)

Application Number Title Priority Date Filing Date
PT101803757T PT2314620E (pt) 2004-05-27 2005-05-26 Método de identificação de moléculas de ligação capazes de neutralizar o vírus da raiva
PT101803989T PT2314621E (pt) 2004-05-27 2005-05-26 Moléculas de ligação capazes de neutralizar o vírus da raiva, e suas utilizações
PT05747901T PT1749029E (pt) 2004-05-27 2005-05-26 Moléculas de ligação capazes de neutralizar o vírus da raiva, e suas utilizações

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PT101803757T PT2314620E (pt) 2004-05-27 2005-05-26 Método de identificação de moléculas de ligação capazes de neutralizar o vírus da raiva
PT101803989T PT2314621E (pt) 2004-05-27 2005-05-26 Moléculas de ligação capazes de neutralizar o vírus da raiva, e suas utilizações

Country Status (23)

Country Link
US (5) US7579446B2 (pt)
EP (3) EP2314620B1 (pt)
JP (1) JP4768730B2 (pt)
KR (2) KR101228157B1 (pt)
CN (5) CN102241769B (pt)
AT (1) ATE501171T1 (pt)
AU (1) AU2005250163B2 (pt)
BR (1) BRPI0511479C1 (pt)
CA (1) CA2568162C (pt)
CU (1) CU23719A3 (pt)
CY (1) CY1111550T1 (pt)
DK (1) DK1749029T3 (pt)
EA (1) EA010785B1 (pt)
ES (2) ES2468021T3 (pt)
HK (3) HK1094705A1 (pt)
HR (3) HRP20110320T1 (pt)
IL (3) IL179586A (pt)
MX (1) MXPA06013482A (pt)
NZ (2) NZ550366A (pt)
PL (3) PL1749029T3 (pt)
PT (3) PT2314620E (pt)
RS (2) RS51847B (pt)
WO (1) WO2005118644A2 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
ES2295639T3 (es) * 2002-06-13 2008-04-16 Crucell Holland B.V. Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion.
WO2004003144A2 (en) 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
EP2395017A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2005000894A2 (en) 2003-06-25 2005-01-06 Crucell Holland B.V. Binding molecules for the treatment of myeloid cell malignancies
AU2004260884B2 (en) * 2003-07-22 2009-11-19 Crucell Holland B.V. Binding molecules against SARS-coronavirus and uses thereof
MXPA06013482A (es) 2004-05-27 2007-03-01 Crucell Holland Bv Moleculas de enlace capaces de neutralizar el virus de la rabia y sus usos.
US7858086B2 (en) * 2004-10-12 2010-12-28 Crucell Holland B.V. Binding molecules for treatment and detection of cancer
WO2006120230A2 (en) 2005-05-12 2006-11-16 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
CA2622603C (en) * 2005-09-15 2014-06-17 Crucell Holland B.V. Method for preparing immunoglobulin libraries
WO2007038407A2 (en) 2005-09-23 2007-04-05 The Regents Of The University Of California Compositions and methods for treating nervous system disorders
US7960518B2 (en) 2006-06-06 2011-06-14 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and uses thereof
HUE027099T2 (hu) 2006-06-06 2016-08-29 Crucell Holland Bv Humán kötõmolekulák staphylococcus elleni ölõaktivitással és alkalmazásuk
AU2007293662B2 (en) 2006-09-07 2012-10-04 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
JP5410985B2 (ja) * 2006-12-05 2014-02-05 クルセル ホランド ベー ヴェー 液体抗狂犬病抗体製剤
HUE027507T2 (en) 2007-06-25 2016-10-28 Esbatech Alcon Biomed Res Unit Procedures for Modifying Antibodies and Modified Antibodies with Improved Functional Properties
JO2913B1 (en) * 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
WO2010132532A1 (en) 2009-05-15 2010-11-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services B cell surface reactive antibodies
WO2011028961A2 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Anti-botulism antibody coformulations
GEP20156214B (en) * 2009-10-02 2015-01-12 Ze Rejents Ov Ze Univ Ov Kalifornia Monoclonal antibodies
CN101696242B (zh) * 2009-10-26 2011-12-28 中国人民解放军南京军区军事医学研究所 人源抗狂犬病毒中和抗体Fab及其制备方法和应用
CN103596975A (zh) * 2010-01-04 2014-02-19 印度免疫有限公司 针对狂犬病病毒的重组人二价双链抗体及其用途
US9365637B2 (en) 2010-02-19 2016-06-14 Japan Science And Technology Agency Antiviral agent, abzyme, primer set, method for producing polynucleotide, and method for producing polypeptide
SG10201903166PA (en) 2010-03-01 2019-05-30 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
CN103003307B (zh) 2010-03-10 2017-08-11 根马布股份公司 抗c‑MEt的单克隆抗体
WO2011159835A1 (en) * 2010-06-16 2011-12-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Antibodies to endoplasmin and their use
KR101388680B1 (ko) * 2011-03-18 2014-04-28 (주)셀트리온 광견병 바이러스를 중화시킬 수 있는 결합 분자
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
WO2013048130A2 (ko) * 2011-09-30 2013-04-04 (주)셀트리온 광견병 바이러스를 중화시킬 수 있는 결합 분자
MX360109B (es) 2012-04-20 2018-10-23 Merus Nv Metodos y medios para la produccion de moleculas de tipo ig.
CN102924571A (zh) * 2012-10-29 2013-02-13 复旦大学 狂犬病毒糖蛋白与核蛋白的抗原表位多肽及其筛选、鉴定方法与应用
CN105814077B (zh) * 2013-12-12 2019-07-26 赛特瑞恩股份有限公司 能够中和狂犬病毒的结合分子
CN103954777A (zh) * 2014-05-20 2014-07-30 北京凯思百奥科技发展有限公司 一种狂犬病病毒单克隆抗体及其应用
RU2549971C1 (ru) * 2014-07-01 2015-05-10 Федеральное казённое учреждение здравоохранения Ставропольский научно-исследовательский противочумный институт Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ консервации иммунопероксидазного конъюгата
CN104761640A (zh) * 2015-02-03 2015-07-08 中国食品药品检定研究院 具有中和活性的抗狂犬病病毒单克隆抗体的制备及应用
WO2016200189A1 (ko) * 2015-06-10 2016-12-15 (주)셀트리온 광견병 바이러스 g 단백질의 에피토프 및 이에 특이적으로 결합하는 광견병 바이러스 중화 결합 분자
US11505599B2 (en) 2016-01-14 2022-11-22 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for Foxp3-derived peptides
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
RU2718835C2 (ru) * 2017-12-29 2020-04-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Нейтрализующее моноклональное антитело, связывающееся с гликопротеином g вируса бешенства, фрагменты днк, кодирующие указанное антитело, и антигенсвязывающий фрагмент
WO2019227039A1 (en) * 2018-05-24 2019-11-28 Lankenau Institute For Medical Research Compositions comprising antibodies to rabies virus and the uses thereof
WO2020029860A1 (zh) * 2018-08-09 2020-02-13 北京智仁美博生物科技有限公司 针对狂犬病病毒的双特异性抗体及其用途
US20220204609A1 (en) * 2019-05-30 2022-06-30 Shandong Boan Biotechnology Co., Ltd. Antibody or chimeric antigen receptor which targets claudin 18.2
CN111171145B (zh) * 2020-01-21 2021-11-05 兰州生物制品研究所有限责任公司 一种抗狂犬病病毒单克隆抗体、制备方法及用途
CN117440973A (zh) * 2021-04-09 2024-01-23 索伦托药业有限公司 与ror1结合的抗原结合蛋白
CN114397453B (zh) * 2022-03-25 2022-06-07 江苏美克医学技术有限公司 新型冠状病毒突变株的检测试剂盒及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
ATE99958T1 (de) * 1989-06-08 1994-01-15 Wistar Inst Monoklonale antikoerper zur behandlung nach einem kontakt mit tollwutvirus.
US6248574B1 (en) 1989-12-13 2001-06-19 Avigdor Shaffermann Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
DE4006630A1 (de) * 1990-03-03 1991-09-12 Behringwerke Ag Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
DE69718341T2 (de) 1996-10-08 2003-10-30 Bisys B V U Verfahren und mittel zur auswahl von peptiden und proteinen mit spezifischer affinität zu einem zielmolekül
EP1533380B1 (en) 1999-04-15 2009-11-04 Crucell Holland B.V. Recombinant protein production in a human cell comprising at least one E1 protein of adenovirus
US20040013672A1 (en) * 2000-05-16 2004-01-22 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
US7071319B2 (en) * 2000-05-16 2006-07-04 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
WO2002103012A1 (en) 2001-06-15 2002-12-27 Crucell Holland B.V. Chimaeric phages
CN1636019B (zh) * 2001-08-21 2010-06-16 托马斯杰斐逊大学 重组抗体的组成以及制作和使用方法
ES2295639T3 (es) 2002-06-13 2008-04-16 Crucell Holland B.V. Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion.
PT2314629E (pt) * 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
US20100069614A1 (en) * 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2005000894A2 (en) 2003-06-25 2005-01-06 Crucell Holland B.V. Binding molecules for the treatment of myeloid cell malignancies
AU2004260884B2 (en) * 2003-07-22 2009-11-19 Crucell Holland B.V. Binding molecules against SARS-coronavirus and uses thereof
WO2005085282A1 (en) 2004-02-27 2005-09-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Il-15 binding site for il15-ralpha and specific il-15 mutants having agonists/antagonists activity
MXPA06013482A (es) * 2004-05-27 2007-03-01 Crucell Holland Bv Moleculas de enlace capaces de neutralizar el virus de la rabia y sus usos.
KR101255861B1 (ko) 2004-11-11 2013-04-17 크루셀 홀란드 비.브이. 사스-코로나바이러스에 대한 조성물 및 그것의 용도
WO2006067122A2 (en) 2004-12-20 2006-06-29 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
WO2006112838A1 (en) 2005-04-18 2006-10-26 Xtl Biopharmaceuticals Ltd. Stabilized anti-hepatitis b (hbv) antibody formulations
WO2006120230A2 (en) 2005-05-12 2006-11-16 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
US20090130652A1 (en) 2005-06-23 2009-05-21 Crucell Holland B.V. Optimization of West Nile Virus Antibodies
JP5135235B2 (ja) * 2006-02-27 2013-02-06 エラン ファーマシューティカルズ，インコーポレイテッド Ｖａｌ−４によって媒介される白血球の接着を阻害するピリミジニルスルホンアミド化合物
HUE027099T2 (hu) * 2006-06-06 2016-08-29 Crucell Holland Bv Humán kötõmolekulák staphylococcus elleni ölõaktivitással és alkalmazásuk
US7960518B2 (en) * 2006-06-06 2011-06-14 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and uses thereof
AU2007293662B2 (en) * 2006-09-07 2012-10-04 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
JP5410985B2 (ja) * 2006-12-05 2014-02-05 クルセル ホランド ベー ヴェー 液体抗狂犬病抗体製剤

Also Published As

Publication number Publication date
EA200602210A1 (ru) 2007-04-27
CN1961002B (zh) 2011-05-18
PT2314621E (pt) 2014-06-23
CN102241769B (zh) 2016-08-10
HK1159651A1 (en) 2012-08-03
DK1749029T3 (da) 2011-06-06
US20080226652A1 (en) 2008-09-18
KR101456770B1 (ko) 2014-10-31
MXPA06013482A (es) 2007-03-01
BRPI0511479A (pt) 2007-12-26
ES2426725T3 (es) 2013-10-24
US7579446B2 (en) 2009-08-25
AU2005250163A1 (en) 2005-12-15
EP2314621A1 (en) 2011-04-27
RS51847B (en) 2012-02-29
IL179586A (en) 2013-06-27
KR101228157B1 (ko) 2013-01-31
CU23719A3 (es) 2011-10-14
IL179586A0 (en) 2007-05-15
RS53269B (en) 2014-08-29
WO2005118644A2 (en) 2005-12-15
AU2005250163B2 (en) 2011-08-25
IL201970A (en) 2014-06-30
US20080070799A1 (en) 2008-03-20
JP4768730B2 (ja) 2011-09-07
CN102212131B (zh) 2013-05-08
NZ550366A (en) 2009-11-27
HK1157680A1 (en) 2012-07-06
IL225849A0 (en) 2013-06-27
PL2314621T3 (pl) 2014-08-29
HRP20110320T1 (hr) 2011-05-31
EP1749029A2 (en) 2007-02-07
ATE501171T1 (de) 2011-03-15
CN102241769A (zh) 2011-11-16
KR20130010130A (ko) 2013-01-25
CA2568162A1 (en) 2005-12-15
US9005624B2 (en) 2015-04-14
CN102212132A (zh) 2011-10-12
PT2314620E (pt) 2013-09-02
PL1749029T3 (pl) 2011-08-31
EA010785B1 (ru) 2008-10-30
US20100272724A1 (en) 2010-10-28
ES2468021T3 (es) 2014-06-13
EP2314621B1 (en) 2014-03-05
BRPI0511479B1 (pt) 2019-01-29
US7740852B2 (en) 2010-06-22
BRPI0511479C1 (pt) 2021-05-25
US20070072177A1 (en) 2007-03-29
JP2008508859A (ja) 2008-03-27
HRP20130750T1 (hr) 2013-10-11
CY1111550T1 (el) 2015-08-05
HRP20140419T1 (hr) 2014-06-06
CN102139106B (zh) 2014-10-08
NZ580607A (en) 2011-05-27
WO2005118644A3 (en) 2006-03-09
CN102212131A (zh) 2011-10-12
CN102139106A (zh) 2011-08-03
US20100310572A1 (en) 2010-12-09
KR20070044807A (ko) 2007-04-30
EP1749029B1 (en) 2011-03-09
US8148497B2 (en) 2012-04-03
HK1094705A1 (en) 2007-04-04
EP2314620B1 (en) 2013-06-05
CN1961002A (zh) 2007-05-09
EP2314620A1 (en) 2011-04-27
PL2314620T3 (pl) 2013-11-29
CA2568162C (en) 2013-04-16

Similar Documents

Publication Publication Date Title
IL225849A0 (en) Molecules with binding ability that can neutralize rabies virus, and their uses
WO2005012360A3 (en) Binding molecules against sars-coronavirus and uses thereof
WO2006067122A3 (en) Binding molecules capable of neutralizing west nile virus and uses thereof
WO2007141274A3 (en) Human binding molecules having killing activity against staphylococci and uses thereof
ATE536376T1 (de) Humanes bindungsmolekül gegen cd1a
IL187321A0 (en) Host cell specific binding molecules capable of neutralizing viruses and uses thereof
WO2007141278A3 (en) Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
WO2011020783A3 (en) Targeted immunoconjugates
WO2008079246A3 (en) Cd44 antibodies
HK1103746A1 (en) Antibodies to erythropoietin receptor and uses thereof
WO2007095316A3 (en) Compositions and methods for oligonucleotide formulations
WO2006003388A3 (en) Compositions and methods for treating inflammatory disorders
MX2009006471A (es) Anticuerpo anti especifico de linfopoyetina estromal timica de diseño.
EA200701825A1 (ru) Вакцины против хламидиоза
WO2008088524A3 (en) Thrombospondin-domain-deficient r-spondin 1 protein as gastrointestinal tract epithelial proliferation factor
WO2008108830A3 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
WO2008085878A3 (en) High affinity antibodies that neutralize staphylcoccus enterotoxin b
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis
WO2008080091A3 (en) Activation of rig-i pathway
WO2005077397A3 (en) Methods and compositions for treating vascular diseases
WO2010114919A3 (en) Metnase and intnase inhibitors and their use in treating cancer
EA201200182A1 (ru) Связывающие человеческие молекулы с киллерной активностью в отношении энтерококков и их применение
WO2004067569A8 (en) Internalising human binding molecules against cd72
DE602004002692D1 (de) Verfahren zur Herstellung von Topiramate
CY1115173T1 (el) Μορια προσδεσης ικανα για εξουδετερωση του ιου λυσσας και χρησεις αυτων